Currently, lung cancer is treated by the highest number of therapeutic options and the
benefits are based on multiple large‐scale sequencing studies, translational research and …

Simple Summary Esophageal and esophagogastric junction cancers are not well explained
by traditional risk factors and have high mortality rates and limited treatment options. The …

Esophageal cancer (EC) is identified as a predominant health threat worldwide, with its
highest incidence and mortality rates reported in China. The complex molecular …

Esophageal cancer is the sixth most common cancer worldwide. Approximately 50% of
patients have locally advanced disease. The CROSS and NEOCRTEC5010 trials have …

Objective This study aimed to identify the effectiveness and safety of PD-1 blockades among
elderly patients with metastatic esophageal squamous cell carcinoma (ESCC) clinically …

Background Nivolumab is approved in Japan as a second-line treatment for patients with
advanced esophageal squamous cell carcinoma (ESCC) resistant to fluoropyrimidine and …

Background Rechallenge with immune checkpoint inhibitor (ICI) seemed favorable in
several tumors, but clinical experience on esophageal squamous cell carcinoma (ESCC) …

Purpose Immune checkpoint inhibitors (ICIs) combined with chemotherapy have become the
first-line standard treatment for locally advanced or metastatic esophageal squamous cell …

BACKGROUND Oral SERDs are a novel drug class that have been developed to counteract
resistance due to ESR1 mutations. Several SERDs have emerged from phase 2 and 3 trials …

Simple Summary Recently, numerous treatments sharing similar mechanisms of action have
been approved for advanced renal cell carcinoma. These combinations prolong survival …